You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR OMONTYS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OMONTYS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00097747 ↗ Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers Completed Affymax Phase 1 2004-08-01 The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.
NCT00109291 ↗ Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease Terminated Affymax Phase 2 2005-03-01 To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.
NCT00228436 ↗ Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Completed Affymax Phase 2 2005-09-01 The purpose of this study was to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneous injections of peginesatide in participants with chronic kidney disease (CKD) not on dialysis who had not received erythropoiesis stimulating agent (ESA) treatment.
NCT00228449 ↗ Peginesatide for Anemia in Chronic Hemodialysis Patients Completed Affymax Phase 2 2005-07-01 The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OMONTYS

Condition Name

Condition Name for OMONTYS
Intervention Trials
Anemia 17
Chronic Kidney Disease 14
Chronic Renal Failure 13
Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OMONTYS
Intervention Trials
Anemia 15
Renal Insufficiency, Chronic 14
Renal Insufficiency 14
Kidney Failure, Chronic 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OMONTYS

Trials by Country

Trials by Country for OMONTYS
Location Trials
United States 160
United Kingdom 10
Poland 5
Bulgaria 4
Romania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OMONTYS
Location Trials
Texas 10
California 10
New York 8
Florida 8
Virginia 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OMONTYS

Clinical Trial Phase

Clinical Trial Phase for OMONTYS
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 11
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OMONTYS
Clinical Trial Phase Trials
Completed 14
Terminated 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OMONTYS

Sponsor Name

Sponsor Name for OMONTYS
Sponsor Trials
Affymax 16
Takeda 9
Amgen 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OMONTYS
Sponsor Trials
Industry 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.